Provenge

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2015
012320042015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
The management of advanced prostate cancer, specifically metastatic castrate-resistant prostate cancer (mCRPC), remains a… (More)
Is this relevant?
Review
2015
Review
2015
Cancer immunotherapy has recently emerged as an important treatment modality. FDA approval of provenge, ipilimumab and… (More)
  • figure 1
  • table 1
Is this relevant?
Review
2011
Review
2011
Sipuleucel-T (PROVENGE; Dendreon) is the first therapeutic cancer vaccine to be approved by the U.S. Food and Drug Administration… (More)
  • figure 1
  • table 1
Is this relevant?
Review
2011
Review
2011
Sipuleucel-T (PROVENGE; Dendreon) is the first therapeutic cancer vaccine to be approved by the U.S. Food and Drug Administration… (More)
  • figure 1
  • table 1
Is this relevant?
2011
2011
 
Is this relevant?
2010
2010
A decade in development, Dendreon’s prostate cancer vaccine, sipuleucelT (Provenge), has become the first therapeutic cancer… (More)
Is this relevant?
Review
2010
Review
2010
man of California’s Stanford University School of Medicine thought he had discovered a way to treat cancer using a vaccine that… (More)
Is this relevant?
2010
2010
The world’s first therapeutic cancer vaccine has been approved by the US Food and Drug Administration (FDA), heralding a major… (More)
Is this relevant?
2007
2007
  • I McKarney
  • Issues in emerging health technologies
  • 2007
(1) Sipuleucel-T (Provenge) is an active cellular immunotherapy (therapeutic vaccine) that is designed to stimulate the patient's… (More)
Is this relevant?
2004
2004
Prostate cancer is an excellent target for an active vaccine-based approach based on the fact that prostate cancer cells express… (More)
Is this relevant?